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Objective: Lung cancer invading the chest wall without lymph node metastasis has
recently been downstaged to stage IIb. To validate this reclassification, we reviewed
our experience with en bloc lung and chest wall resection for bronchogenic carci-
noma.
Methods: From February 1985 to November 1999, 95 en bloc lung and chest wall
resections were performed on 94 patients (62 men and 32 women). The median age
was 66 years (range, 38-93 years). Pancoast tumors were excluded. Factors that may
affect survival were analyzed with univariate analysis, and factors found to be
significant univariately were analyzed multivariately to determine whether the
significant association remained after adjusting for other significant factors.
Results: Presenting symptoms included chest wall pain in 42 patients, cough in 17
patients, and “other” in 16 patients. Twenty patients were asymptomatic. Ninety-
two patients were current or former smokers (median pack-years, 50; range, 8-150
pack-years). Seventy-five lobectomies, 12 pneumonectomies, 5 bilobectomies, 2
wedge excisions, and 1 segmentectomy were performed. The number of ribs
resected ranged from 1 to 5 (median, 3). Sixty-one patients required chest wall
reconstruction (prostheses in 60 and bovine pericardium in 1). Operative morbidity
and mortality were 44.2% and 6.3%, respectively. Sixty-five cancers were classified
as T3 N0 M0, 16 as T3 N1 M0, and 14 as T3 N2 M0. Squamous cell carcinoma was
present in 56 tumors, adenocarcinoma in 25, large cell carcinoma in 11, and “other”
in 3. Follow-up was complete in 86 (96.6%) of 89 operative survivors and ranged
from 1 month to 15 years (median, 19 months). Overall 5-year actuarial survival was
38.7%. Five-year survival for patients with stage IIb disease (T3 N0 M0) was 44.3%
compared with only 26.3% for those with stage IIIa disease (T3 N1 M0 or T3 N2
M0, P  .0082). Women had a better 5-year survival than men (52.9% vs 31.0%,
P  .0122). The best 5-year survival was observed in women with stage IIb disease
(61.2%). All other variables (age, tumor size, histopathology, forced expiratory
volume in 1 second, extent of operation, depth of invasion, and adjuvant therapy)
did not significantly affect survival.
Conclusions: En bloc resection of lung cancer invading the chest wall is safe but
associated with significant morbidity. Long-term survival is stage and sex depend-
ent. The best survival is observed in women who have T3 N0 M0 disease (stage IIb).
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Lung cancer remains the most common causeof cancer deaths in the United States. Unfor-tunately, most patients have advanced dis-ease at the time of diagnosis and are notcandidates for surgical resection. Chest wallinvasion historically has been considered
unresectable; however, recent studies have demonstrated
that invasion does not have an adverse effect on survival if
lymph node metastases have not occurred.1-3 As a result, T3
N0 M0 lung cancers invading the chest wall have been
downstaged to stage IIb.4 To validate the reclassification,
we have reviewed our most recent experience with en bloc
lung and chest wall resection for lung cancer.
Materials and Methods
Between February 1985 and November 1999, 94 patients under-
went 95 en bloc lung and chest wall resections at the Mayo Clinic
in Rochester, Minnesota, for bronchogenic carcinoma. During this
same period of time, from February 1985 to November 1999, 5666
patients underwent pulmonary resection for bronchogenic carci-
noma. Metastatic, T4, and Pancoast tumors were excluded. Med-
ical records were reviewed for patient demographics, preoperative
symptoms, pulmonary function, operative procedures, tumor cell
type and stage, and survival. Follow-up was obtained by means of
office visits, telephone interviews, or both.
Cancers were staged according to the revised international
staging system.4 The depth of chest wall invasion was grouped into
3 levels on the basis of the pathology report: parietal pleura only;
parietal pleura and soft tissue; and parietal pleura, soft tissue, and
bone. Survival statistics were performed with the Kaplan-Meier
method, with the day of operation as the starting point.5 Operative
mortality included all deaths within 30 days of operation and those
deaths that occurred later but during the same hospitalization.
Survival curves were compared with the log-rank test. Factors that
affected survival significantly with univariate analysis were ana-
lyzed multivariately with the Cox proportional hazards model.6
Results
There were 62 men and 32 women in the study. One man
had 2 separate operations for different metachronous pri-
mary lung cancers, both of which involved the chest wall.
Median age was 66 years and ranged from 38 to 93 years.
Ninety-two patients were current or former smokers (medi-
an, 50 pack-years; range, 8-150 pack-years). Presenting
symptoms are shown in Table 1. Chest pain was the most
common presenting symptom and occurred in 42 patients.
Other symptoms included cough in 17 patients, pneumonia
in 5, dyspnea in 4, malaise in 4, and “other” in 3. Twenty
patients were asymptomatic.
Rib destruction was observed on chest roentgenography
in 12 patients and on chest computed tomography in 17
patients. Pulmonary function tests were available in 88
patients. The median forced expiratory volume in one sec-
ond (FEV1) was 2.19 L (range, 0.81-3.8 L). Four patients
had severe respiratory impairment (FEV1 40%). The me-
dian percentage of predicted diffusion capacity for carbon
monoxide and maximum voluntary ventilation were 74%
(range, 36%-119%; n  67 patients) and 79% (range, 32%-
141%; n 81 patients), respectively. Preoperative radiation
therapy was administered to 4 patients, chemotherapy to 2
patients, and both to 3 patients.
Mediastinoscopy was performed in 45 patients and
showed no evidence of lymph node metastasis in all pa-
tients. A posterolateral thoracotomy approach was used in
all patients. A lobectomy was performed for 75 of the
tumors, a pneumonectomy for 12, bilobectomies for 5,
wedge excision for 2, and segmentectomy for 1. All patients
had full-thickness en bloc chest wall resection. Our intra-
operative approach for patients who may have chest wall
invasion is to open the chest cavity away from the site of
attachment and to assess the degree of invasion by means of
manual palpation. If the tumor is invading the chest wall, we
resect the chest wall with a free margin of approximately 1.0
to 2.0 cm. Extrapleural resections are performed only if
there are flimsy adhesions to the chest wall. The median
number of ribs resected was 3 and ranged from 1 to 5. No
patient had resection of the sternum. All patients had com-
plete mediastinal lymph node dissection. All cancers were
completely resected (R0), and the chest wall margins were
histologically negative in all patients. The bony chest wall
was reconstructed in 61 patients with a polytetrafluoroeth-
ylene soft-tissue patch in 60 and a bovine pericardium in 1.
Reconstruction of the chest wall was performed if there was
a sizable defect that would not be covered by the scapula.
This usually meant a defect of at least 4.0 cm in diameter or
one on which the tip of the scapula might catch. Nineteen
patients received postoperative adjuvant therapy (chemo-
therapy in 3 patients, radiation therapy in 8, and both in 8).
The TNM classification of the tumors is shown in Table
2. Sixty-five tumors were T3 N0 M0. Depth of invasion was
TABLE 1. Presenting signs and symptoms








TABLE 2. TNM staging
Stage TNM stage (4) No. of tumors
IIb T3 N0 M0 65
IIIa T3 N1 M0 16
T3 N2 M0 14
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able to be determined in 95 specimens. The depth of inva-
sion was into the parietal pleura only in 29 tumors, the
parietal pleura and soft tissue in 43 tumors, and the parietal
pleura, soft tissue, and bone in 23 tumors. Lymph node
metastases occurred in 30 patients (16 with N1 and 14 with
N2 disease). Squamous cell carcinoma was present in 56
cancers, adenocarcinoma in 25, large cell carcinoma in 11,
and small cell, undifferentiated, and sarcomatoid carcinoma
in 1 each. The median diameter of the tumor was 6.0 cm and
ranged from 1.2 to 14.0 cm.
The median hospitalization was 10 days (range, 4-105
days). Forty-two patients had postoperative complications,
as shown in Table 3, and included atrial fibrillation in 16,
pneumonia in 9, prolonged air leak in 5, chylothorax in 3,
postoperative bleeding in 3, a cerebral spinal fluid leak from
a dural tear in 1, bronchopleural fistula in 1, and middle lobe
torsion in 1. Eleven patients required prolonged mechanical
ventilation, 9 of whom required tracheostomy. There were 6
operative deaths (mortality, 6.3%). Cause of death was
myocardial infarction in 2 patients and pneumonia, pulmo-
nary emboli, multisystem organ failure caused by sepsis,
and a cerebrovascular accident in 1 each. Mortality was
5.3% (4 patients) for lobectomy and 8.3% (1 patient) for
pneumonectomy. Operative mortality was 4.6% (3 patients)
for T3 N0 M0 tumors, 6.2% (1 patient) for T3 N1 M0
tumors, and 14.3% (2 patients) for T3 N2 M0 tumors.
Follow-up was complete in 86 (96.6%) of the 89 oper-
ative survivors and ranged from 1 month to 15 years (me-
dian, 19 months). Twenty-three patients are currently alive.
The overall 5-year actuarial survival was 38.7% (95% con-
fidence interval [CI], 29.4%-50.7%; Figure 1). Survival was
stage dependent (Figure 2). Five-year survival for patients
with stage IIb cancers (T3 N0 M0) was 44.3% (95% CI,
32.9%-59.1%) compared with 26.3% (95% CI, 13.7%-
50.5%) for patients with stage IIIa cancers (T3 N1 M0 or T3
N2 M0, P  .0082).
Univariate analysis revealed that women had a better
5-year survival than men (Figure 3). The overall 5-year
survival for women was 52.9% (95% CI, 37.5%-74.6%)
compared with only 31.0% (95% CI, 20.6%-46.0%) for men
(P  .0122). The best 5-year survival was observed in
women with stage IIb disease (61.2%; 95% CI, 42.1%-
88.9%). The 5-year survival for men with stage IIb disease
was 36.4% (95% CI, 23.8%-54.8%), and that for men with
stage IIIa disease was 16.0% (95% CI, 4.8%-54.0%). The
5-year survival for women with stage IIb disease was 61.2%
(95% CI, 42.1%-88.9%), and that for women with stage IIIa
disease was 38.1% (95% CI, 17.9%-81.1%). Survival varied
by depth of invasion. The 5-year survival for tumors that
invaded the parietal pleura only was 49.9% (95% CI,
33.6%-74.1%), that for tumors that invaded soft tissue and
the parietal pleura was 35.0% (95% CI, 22.6%-53.5%), and
that for tumors that invaded bone was 31.6% (95% CI,
15.7%-60.5%; Figure 4). These differences were not statis-
tically significant. Survival was not affected by age, tumor
size, cell type, FEV1, or preoperative or postoperative ad-
juvant therapy.
Sex remained significantly associated (P  .008) with
Figure 1. Actuarial cumulative probability Kaplan-Meier esti-
mates of survival after en bloc lung and chest wall resection.
Zero years on the abscissa represents the date of the operation.
Numbers in parentheses represent patients at risk.
Figure 2. Actuarial cumulative probability Kaplan-Meier esti-
mates of survival after en bloc lung and chest wall resection
compared by postsurgical stage. Zero years on the abscissa
represents the date of the operation. Numbers in parentheses
represent patients at risk.
TABLE 3. Postoperative complications
Complication Number of patients
Atrial fibrillation 16
Pneumonia 9
Prolonged air leak 5
Chylothorax 3
Postoperative bleeding 3
Cerebrospinal fluid leak from dural tear 1
Bronchopleural fistula 1
Middle lobe torsion 1
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survival after adjusting for stage of disease (risk ratio for
male patients was 2.2 times that for female patients; 95%
CI, 1.2-3.9). Stage of disease also remained significantly
associated (P  .005) with survival after adjusting for sex
(risk ratio for patients with stage IIIa disease was 2.2 times
that of patients with stage IIb disease; 95% CI, 1.3-3.6).
Discussion
Patients with lung cancer and contiguous chest wall inva-
sion represent less than 8% of all patients with primary lung
cancer.7 Controversy persists regarding optimal treatment of
these patients. Historically, lung cancer invading the chest
wall was considered unresectable. However, 50 years ago,
Coleman8 described 2 long-term survivors who underwent
en bloc lung and chest wall resection. Since that initial
report, there have been several larger series that have dem-
onstrated that survival after en bloc resection approaches
that of patients with T2 cancers if lymph node metastases
have not occurred.9 This observation has resulted in T3 N0
M0 lung cancer being downstaged from IIIa to IIb. This
report examines our most recent experience with en bloc
lung and chest wall resection for lung cancer and reconfirms
the efficacy of resection.
The absence of lymph node metastasis in our study was
a significant predictor of long-term survival. Others have
reported this similar finding.3,7,10 Given the poor 5-year
survival and increased morbidity encountered in patients
with positive N2 lymph nodes, we would not recommend
surgical resection for these patients. They should be treated,
however, as part of a clinical trial. Female sex was also a
predictor of improved survival. Other reports have demon-
strated improved survival in women.11-14 In 1985, our insti-
tution reported a 45-year prevalence study of lung cancer in
Olmsted County, Minnesota.11 Women had a better 5-year
survival for all lung cancer cell types, except small cell
carcinoma. When compared by stage, Ouellette and col-
leagues14 demonstrated that women lived 12 months longer
than men. This finding of prolonged survival in women may
be a statistical aberration; however, it is present in 3 sepa-
rate studies. If it is a real finding, the reasons this occurs are
unclear at present and await further examination.
Little information exists regarding adjuvant chemother-
apy for lung cancers invading the chest wall. Although
preoperative chemotherapy has recently been demonstrated
to improve resectability and overall survival in patients with
Pancoast tumors,15 no comparable data exist to suggest that
preoperative chemotherapy improves survival for lung can-
cer invading the chest wall. Radiation therapy has been used
more often but still remains controversial. Several studies
have analyzed the advantages and disadvantages of radia-
tion therapy administered both preoperatively and postop-
eratively. The potential benefits of preoperative radiation
therapy include improving resectability by downstaging the
tumor, reducing the chance for seeding at the time of
resection, and reducing the amount of radiation required
postoperatively. In 1982, Patterson and associates1 demon-
strated a 5-year survival of 56% for patients receiving
radiation therapy postoperatively compared with only 30%
for those who did not. However, their results were not
statistically significant. More recently, Facciolo and col-
leagues7 observed a 5-year survival of 74.1% after radiation
therapy compared with only 46.7% for patients who did not
receive radiation therapy (P .023). However, other series,
including our previous report, the Massachusetts General
Hospital’s report, Memorial Sloan-Kettering Cancer Cen-
ter’s report, and a recent series from France have not dem-
onstrated any improvement in survival with the use of
radiation therapy.2,3,10,16 One report did demonstrate an in-
creased operative mortality with the administration of pre-
operative radiation therapy.17
Figure 4. Actuarial cumulative probability Kaplan-Meier esti-
mates of survival after en bloc lung and chest wall resection
compared by depth of invasion. Zero years on the abscissa
represents the date of operation. Numbers in parentheses repre-
sent patients at risk.
Figure 3. Actuarial cumulative probability Kaplan-Meier esti-
mates of survival after en bloc lung and chest wall resection
compared by sex. Zero years on the abscissa represents the date
of the operation. Numbers in parentheses represent patients at
risk.
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As with other series, complications occurred in nearly
half of our patients, and pulmonary and cardiovascular
complications accounted for most of these complica-
tions.7,10 Our operative mortality was 6% and compared
favorably with our past experience and that reported by
others.2,7,10 Prevention of complications is best accom-
plished by selecting the appropriate procedure for a given
patient, meticulous surgical technique, and dedicated peri-
operative care.
Controversy exists as to whether full-thickness resection
is necessary in all patients, especially those with invasion
limited to the parietal pleura. Although some investigators
have reported that the depth of tumor invasion is a prog-
nostic indicator of survival, both the current study and
earlier reports from our institution did not demonstrate that
tumor depth was a predictor of survival.2,3,10,18 We have
previously reported that full-thickness chest wall resection
had superior survival results compared with those of ex-
trapleural resections, and therefore our practice has been to
perform full-thickness chest wall resections for all depths of
lung cancers invading the chest wall.19 Nonetheless, full-
thickness resection for all patients remains controversial.
In summary, en bloc resection of bronchogenic carci-
noma invading the chest wall is safe but associated with
significant morbidity. Long-term survival is stage and sex
dependent. The best survival was observed in women with
stage IIb disease.
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Discussion
Dr Eric Vallieres (Seattle, Wash). Over the years, it has
become accepted that surgical resection is the key component in
the management of most patients with non–small cell lung cancer
and direct parietal involvement. Controversies, however, remain as
to how extensive a resection should be, on what the place of
induction therapy may be, and, if so, what type, and, finally, on
what the role of adjuvant therapy may be. Most of us answer these
questions on the basis of personal opinions that have evolved over
the years, either from reviewing our own experiences with the
disease or from reviewing published single-institution series sim-
ilar to this one from the Mayo Clinic in Rochester. There are no
randomized data to answer the questions. The Lung Cancer Study
Group attempted a study in the early 1980s that closed prematurely
owing to poor accrual, and with only 5% to 8% of all non–small
cell lung cancers presenting in this manner, it is unlikely that phase
III data will ever be available to guide us.
Your results really compare with previously reported series in
terms of operative morbidity, mortality, and survival. This 14-year
series of 95 resections has its merits in that it is uniform by
spanning an era where computed tomographic assessment was
available for all patients. In addition, all patients in this series
underwent an en bloc chest wall resection, whatever the depth of
parietal invasion was judged to be at exploration. This is, to my
knowledge, the third or fourth series on the topic by the Mayo
group, which has, over the years, contributed significantly to our
knowledge of the problem.
I have the following questions. We know from your and others’
experiences that completeness of resection is one of the most
important predictors of survival with this group of patients. I note
that every patient in this series had an R0 resection. Did you
restrict your analysis to R0 resected patients, or did you really
consecutively achieve such statistics? If so, what preoperative
evaluation allowed you such results?
Second, it is my understanding that since Mayo’s review of the
topic in 1994 by Vic Trastek, it has been your institutional policy
to perform en bloc chest wall resection in all patients and never
attempt extrapleural resection, whatever the findings are at explo-
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ration. This remains a subject of controversy. How many patients
treated along those lines were found pathologically to have T2
disease and would have been excluded from this series, and what
happened to these patients?
Third, 43% of your patients presented with pain. Twenty-one
percent were asymptomatic. Did pain at presentation affect prog-
nosis? Did pain at presentation correlate with depth of chest wall
invasion? Did radiologic bone destruction seen preoperatively in
17 patients imply a worse prognosis?
You described that 34 patients required no chest wall recon-
struction and that 61 did. Was there a correlation with the presence
or absence of a chest wall reconstruction and the occurrence of
acute postoperative respiratory difficulties encountered in 11 pa-
tients?
Finally, in your conclusion you have noted that, stage for stage,
women have a better prognosis than men for this disease. Were
these tumors biologically different? Was molecular evaluation of
these lesions performed?
Dr Burkhart. Thank you, Dr Vallieres, for your comments. I
will take them in order here.
All of the resections that we included in this study were
complete resections (R0). Our standard preoperative radiologic
evaluation was computed tomography of the chest and upper
abdomen. Patients with incomplete resections because of invasion
into the spine were not included in this series.
We prefer a full-thickness chest wall resection on any patient
who has a cancer that invades the chest wall. For patients that have
loose adhesions from the lung to the chest wall, we would resect
the pleura locally for those tumors, but these were T2 tumors and
not included in this series.
Pain at presentation did not correlate with long-term survival.
We looked at it with univariate analysis, and there was no corre-
lation with survival.
We did not examine whether chest wall reconstruction was
associated with a higher rate of respiratory difficulty. My impres-
sion is that it was not related.
There was no difference in the stage or histologic types of the
cancers between men and women. Two thirds of the women had
T3 N0 lesions, and two thirds of the men did. We did not perform
any molecular evaluations on these tumors.
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